Security record · archived quarter
ALMS
Alumis Inc. · Healthcare · Biotechnology
3Tracked holders
-1Δ holders
573.51KShares held
$6.13MReported value
+1New positions
−2Exits
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q3 2024
Ownership over time
| Quarter | Holders | Δ | Shares | Reported value | New | Exits |
|---|---|---|---|---|---|---|
| Q2 2026 | 75 | 0 | 42.53M | $1.19B | +6 | −6 |
| Q1 2026 | 78 | +19 | 38.58M | $847.29M | +25 | −6 |
| Q4 2025 | 58 | +2 | 18.95M | $184.97M | +2 | — |
| Q3 2025 | 15 | +2 | 13.24M | $52.83M | +2 | — |
| Q2 2025 | 10 | +3 | 10.75M | $32.25M | +5 | −2 |
| Q1 2025 | 4 | -1 | 688.93K | $4.23M | +1 | −2 |
| Q4 2024 | 5 | +1 | 715.32K | $5.62M | +1 | — |
| Q3 2024 | 3 | -1 | 573.51K | $6.13M | +1 | −2 |
| Q2 2024 | 4 | — | 543.74K | $7.23M | — | — |
Who holds it · Q3 2024
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Geode Capital Management ✦ (passive) | 305.68K | New | $3.27M | 0.0% | New | 1 | SEC ↗ |
| 2 | Geode Capital Management ✦ (passive) | 305.68K | New | $3.27M | 0.0% | New | 1 | SEC ↗ |
| 3 | Norges Bank ✦ (passive) | 226.31K | -9.5% | $2.42M | 0.0% | ▼ Trim | 2 | SEC ↗ |
| 4 | Citadel Advisors ✦ | 41.52K | +98.5% | $443,423 | 0.0% | ▲ Add | 2 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Geode Capital Management | $3.27M | 0.0% |
| Geode Capital Management | $3.27M | 0.0% |
Exited
| Millennium Management | $3.38M | was 0.0% |
| Two Sigma Investments | $252,700 | was 0.0% |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 194 holders, 98.56M shares, $2.09B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
Frequently co-owned
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Provenance: Ownership from parsed 13F common-stock positions (tracked universe, comparable sets for changes); insider rows from Forms 3/4/5; stakes from Schedules 13D/13G; every filing links to its original on SEC EDGAR.
Reporting period: Q3 2024 ·
Methodology ·
Get this via the API